Phathom PharmaceuticalsPHAT
About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees: 427
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
131% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 26
64% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 22
8% more funds holding
Funds holding: 133 [Q3] → 144 (+11) [Q4]
8.86% less ownership
Funds ownership: 106.36% [Q3] → 97.51% (-8.86%) [Q4]
42% less funds holding in top 10
Funds holding in top 10: 12 [Q3] → 7 (-5) [Q4]
59% less capital invested
Capital invested by funds: $1.31B [Q3] → $541M (-$771M) [Q4]
91% less call options, than puts
Call options by funds: $455K | Put options by funds: $5.2M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Joseph Stringer 24% 1-year accuracy 27 / 112 met price target | 575%upside $28 | Buy Reiterated | 21 Apr 2025 |
Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target | 141%upside $10 | Neutral Maintained | 17 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 23% 1-year accuracy 16 / 69 met price target | 575%upside $28 | Buy Reiterated | 7 Mar 2025 |
Financial journalist opinion
Based on 8 articles about PHAT published over the past 30 days









